A United Arab Emirates company is nearing the end of Phase III clinical trials of a Chinese COVID-19 vaccine and hopes to manufacture it next year, a representative said.
The trial, which began in mid-July, is a partnership between Sinopharm’s China National Biotec Group and Abu Dhabi-based artificial intelligence and cloud computing company Group 42 .
It has been administered to more than 31,000 people in the UAE, Egypt, Bahrain and Jordan, G42 Healthcare CEO Ashish Koshy said.He said G42 has distribution and manufacturing agreements with Sinopharm and hopes to provide the UAE and other regional states with the vaccine, especially those that participated in the trial.“Early results are showing it is safe, there is a general rise in antibodies for all the volunteers,” Koshy said.
“I work in a hospital so it was something that we want to help with,” she said. “We trust our country.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
'Jurassic World: Dominion' halts production due to positive COVID-19 test
Read more »
UK considering more local COVID-19 curbs as virus spreads, minister saysBritish Prime Minister Boris Johnson's government is considering additional local COVID-19 restrictions for parts of northern England as the second wave of the novel coronavirus accelerates, Housing Secretary Robert Jenrick said on Thursday.
Read more »
Q&A: Where are we in the COVID-19 vaccine race?Drugmakers and research centers around the world are working on COVID-19 vaccines, with large global trials of several of the candidates involving tens of thousands of participants well underway.
Read more »
FDA wants two months of safety data before considering Covid-19 vaccineThe US FDA made clear it will want to see two months of follow-up data after volunteers get their second dose of vaccine as part of clinical trials testing potential coronavirus vaccines.
Read more »